Kavita Sahai1, Vandana Gangadharan2, H P Singh3, N S Mani4. 1. Senior Advisor (Pathology), Base Hospital, Delhi Cantt-10. 2. Pathologist, Holovision Diagnostics, Port Blair. 3. Senior Advisor (Medicine & Medical Oncology), Command Hospital (CC), Lucknow. 4. Commandant, MH, Jaipur.
Abstract
INTRODUCTION: Diffuse large B cell lymphomas (DLBCL) encompass a pathogenetically heterogeneous group of aggressive tumours that are rapidly fatal if untreated. Gene expression profiling studies have identified distinct molecular subtypes of DLBCL, one with an expression profile similar to normal germinal centre B cells (GCB subtype) and a second mimicking activated peripheral blood B cells (ABC subtype) having different prognostic significance allowing risk stratification of lymphoma patients and development of specific therapeutic strategies. METHODS: Twenty cases of DLBCL were included in the study and categorized into germinal centre and non germinal centre subtypes using the following antibody panel. CD10, Bcl-6, MUM1 and CD138. The germinal centre and non germinal centre subtypes were defined as under Germinal centre (DLBCL) CD10 + and/or Bcl-6 +, MUM1 -, CD138 - and Non germinal centre (DLBCL) CD10, Bcl-6 ±, MUM1 ±, CD138 ±. RESULT: In our study of twenty cases thirteen were germinal centre DLBCL while seven of the twenty cases were non germinal centre type of DLBCL. 75% of the nodal cases and 62.5% of extra nodal cases were germinal centre B cell type. Overall survival in the GCB and non GCB groups was 91% and 14% respectively and the difference was highly significant statistically. CONCLUSION: This study validates the existence of prognostic subgroups of DLBCL in the Indian population.
INTRODUCTION: Diffuse large B cell lymphomas (DLBCL) encompass a pathogenetically heterogeneous group of aggressive tumours that are rapidly fatal if untreated. Gene expression profiling studies have identified distinct molecular subtypes of DLBCL, one with an expression profile similar to normal germinal centre B cells (GCB subtype) and a second mimicking activated peripheral blood B cells (ABC subtype) having different prognostic significance allowing risk stratification of lymphomapatients and development of specific therapeutic strategies. METHODS: Twenty cases of DLBCL were included in the study and categorized into germinal centre and non germinal centre subtypes using the following antibody panel. CD10, Bcl-6, MUM1 and CD138. The germinal centre and non germinal centre subtypes were defined as under Germinal centre (DLBCL) CD10 + and/or Bcl-6 +, MUM1 -, CD138 - and Non germinal centre (DLBCL) CD10, Bcl-6 ±, MUM1 ±, CD138 ±. RESULT: In our study of twenty cases thirteen were germinal centre DLBCL while seven of the twenty cases were non germinal centre type of DLBCL. 75% of the nodal cases and 62.5% of extra nodal cases were germinal centre B cell type. Overall survival in the GCB and non GCB groups was 91% and 14% respectively and the difference was highly significant statistically. CONCLUSION: This study validates the existence of prognostic subgroups of DLBCL in the Indian population.
Entities:
Keywords:
Diffuse large B cell lymphoma (DLBCL); Germinal centre B subtype; Immunohistochemical subtypes; Non germinal centre subtype; Prognosis
Authors: Gustaaf W van Imhoff; Evert-Jan G Boerma; Bronno van der Holt; Ed Schuuring; Leo F Verdonck; Hanneke C Kluin-Nelemans; Philip M Kluin Journal: J Clin Oncol Date: 2006-09-01 Impact factor: 44.544
Authors: B Falini; M Fizzotti; A Pucciarini; B Bigerna; T Marafioti; M Gambacorta; R Pacini; C Alunni; L Natali-Tanci; B Ugolini; C Sebastiani; G Cattoretti; S Pileri; R Dalla-Favera; H Stein Journal: Blood Date: 2000-03-15 Impact factor: 22.113
Authors: A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt Journal: Nature Date: 2000-02-03 Impact factor: 49.962
Authors: Daphne de Jong; Andreas Rosenwald; Mukesh Chhanabhai; Philippe Gaulard; Wolfram Klapper; Abigail Lee; Birgitta Sander; Christoph Thorns; Elias Campo; Thierry Molina; Andrew Norton; Anton Hagenbeek; Sandra Horning; Andrew Lister; John Raemaekers; Randy D Gascoyne; Gilles Salles; Edie Weller Journal: J Clin Oncol Date: 2007-03-01 Impact factor: 44.544
Authors: C Adida; C Haioun; P Gaulard; E Lepage; P Morel; J Briere; H Dombret; F Reyes; J Diebold; C Gisselbrecht; G Salles; D C Altieri; T J Molina Journal: Blood Date: 2000-09-01 Impact factor: 22.113
Authors: Chung-Che Chang; Sara McClintock; Ronald P Cleveland; Trent Trzpuc; David H Vesole; Brent Logan; Andre Kajdacsy-Balla; Sherrie L Perkins Journal: Am J Surg Pathol Date: 2004-04 Impact factor: 6.394
Authors: Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan Journal: Blood Date: 2003-09-22 Impact factor: 22.113